Table 1 Recalls, mean, and median rankings of 80 FDA-approved RA drugs when four TreatKBs were used separately and in tandem
From: A genomics-based systems approach towards drug repositioning for rheumatoid arthritis
TreatKB | Recall | Mean ranking | Median ranking |
|---|---|---|---|
FDA-approved | 0.825 | 36.58 % | 34.46 % |
Post-market | 0.775 | 19.02 % | 8.53 % |
Clinical trials | 0.750 | 31.73 % | 29.24 % |
Literature | 0.663 | 29.69 % | 19.17 % |
Combined | 0.925 | 20.06 % | 8.93 % |